Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8611 to 8625 of 9045 results

  1. Lasmiditan for treating acute migraine [ID3759]

    Discontinued Reference number: GID-TA10807

    Technology appraisal guidance
    Discontinued

  2. Anaphylaxis: assessment and referral after emergency treatment (CG134)

    This guideline has been updated and replaced by NICE guideline NG258.

    Withdrawn guideline

  3. Ticagrelor for preventing stroke after previous ischaemic stroke or high-risk transient ischaemic attack [ID2689]

    Discontinued Reference number: GID-TA10663

    Technology appraisal guidance
    Discontinued

  4. Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223

    Discontinued Reference number: GID-HST10019

    Highly specialised technologies guidance
    Discontinued

  5. Arimoclomol for treating Niemann-Pick disease Type C [ID1312]

    In development Reference number: GID-HST10037 Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  6. GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain

    In development Reference number: GID-MT567 Expected publication date: TBC

    Medical technologies guidance
    In development

  7. Pegvaliase for treating phenylketonuria [ID1110]

    Discontinued Reference number: GID-TA10345

    Technology appraisal guidance
    Discontinued

  8. Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]

    Discontinued Reference number: GID-TA11433

    Technology appraisal guidance
    Discontinued

  9. Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over [ID6475]

    In development Reference number: GID-TA11586 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Zio XT for detecting cardiac arrhythmias

    In development Reference number: GID-MT591 Expected publication date: TBC

    Medical technologies guidance
    In development

  11. Risdiplam for treating spinal muscular atrophy (TA755)

    This guidance has been updated and replaced by NICE's technology appraisal guidance on nusinersen and risdiplam for treating spinal muscular atrophy (TA1162).

    Withdrawn guidance

  12. Nusinersen for treating spinal muscular atrophy (TA588)

    This guidance has been updated and replaced by NICE's technology appraisal guidance on nusinersen and risdiplam for treating spinal muscular atrophy (TA1162).

    Withdrawn guidance

  13. Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]

    Discontinued Reference number: GID-TA11569

    Technology appraisal guidance
    Discontinued

  14. Lung cancer (non-small cell, advanced, inoperable) - liposomal cisplatin (with chemotherapy) [ID657]

    Discontinued Reference number: GID-TAG496

    Technology appraisal guidance
    Discontinued

  15. Everolimus with exemestane for treating HER2-negative hormone-receptor-positive breast cancer after endocrine therapy [ID965]

    Discontinued Reference number: GID-TA10028

    Technology appraisal guidance
    Discontinued